84 results
Page 3 of 5
8-K
EX-10.1
850o3w
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
EX-10.46
p3uoxumkpik
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
EX-10.47
zrhbvvzv0xuh
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
EX-10
jh6mo
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
EX-2.1
9ddrx8uvnkgnc9
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
8-K
EX-4.1
f3h7xwjmie5 vsh1
10 Dec 12
Entry into a Material Definitive Agreement
12:00am